Skip to content

Study · Not a test of the peptide alone · 2021

2 results

The protective effect of fenofibrate, triptorelin, and their combination against premature ovarian failure in rats.

Abdelzaher WY, Abdel-Hafez SMN, Rofaeil RR, Ali AHSA, Hegazy A, Bahaa HA

Naunyn-Schmiedeberg's archives of pharmacology14 Sept 2020Cited by 31 (Europe PMC)

PMID32924068 (opens in a new tab)DOI10.1007/s00210-020-01975-2 (opens in a new tab)PepBankPUB-32924068
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Efficacy outcome

    In rats with cyclophosphamide-induced ovarian failure, fenofibrate plus triptorelin increased follicle counts versus cyclophosphamide alone.

    In plain wordsIn rats, fenofibrate plus triptorelin increased ovarian follicle counts compared with cyclophosphamide alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseOvarian follicle count
    Study

    ratn: not reported in source

    cyclophosphamide-induced premature ovarian failure
    Comparator
    cyclophosphamide group
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Ovarian follicle count
    5.75 follicles
    fenofibrate plus triptorelin

    Source sentences

    Summary
    Meanwhile, FEN, either solely or in combination with TRI, significantly increased ovarian follicle count, as compared with the CP group (3.88 ± 0.83 and 5.75 ± 1.39, respectively).
    1 context sentence
    Summary · context
    Rats were randomly divided into five groups as follows: negative control, CP, triptorelin (TRI)-treated, FEN (FEN)-treated, and FEN + TRI-treated.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Efficacy outcome

    In rats with cyclophosphamide-induced ovarian failure, fenofibrate plus triptorelin improved the previously listed parameters versus cyclophosphamide injury.

    In plain wordsIn rats, fenofibrate plus triptorelin improved the listed parameters compared with cyclophosphamide injury.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableOverall measured parameter improvement
    Study

    ratn: not reported in source

    cyclophosphamide-induced premature ovarian failure
    Comparator
    cyclophosphamide group
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Administration of FEN either solely or in combination with TRI showed significant improvement in all the parameters previously mentioned.
    2 context sentences
    Summary · context
    As compared with the control group, CP increased the levels of MDA, NOx, IL-10, TNF-α, FSH, LH, and collagen area fraction; however, levels of GSH, SOD, VEGF, AMH, estrogen, and PCNA immunoexpression were reduced with CP.
    Summary · context
    Rats were randomly divided into five groups as follows: negative control, CP, triptorelin (TRI)-treated, FEN (FEN)-treated, and FEN + TRI-treated.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.